Lower extremity chronic deep venous insufficiency (CDVI) is common and remains a major health problem worldwide. Selected patients benefited from direct deep vein valve surgical repair or valve transplantation. A major limitation of this approach is that most of the patients are not candidates for these procedures due to obstructions or residual thrombus throughout the vein. The past 15 years have witnessed experimental efforts at catheter-based management of CDVI. This review describes the initial designs and experimental evolution of a mechanical and bioprosthetic venous valve that can be implanted by using a transcatheter technique. These valves consisted of single, double, or triple cusp leaflets made of synthetic or biological materials attached to a carrier or frame. All described devices for percutaneous transcatheter valve placement rely on some form of a vascular stent for valve attachment.
The venous system and chronic deep venous insufficiency
The circulatory venous system of the lower extremities is in part composed of superficial, deep, and perforating (connecting superficial to deep) veins. 1 The pumping of the leg muscles facilitates venous return by moving blood along the veins. Venous valves assist this pumping mechanism. In the human upright posture, normal closing of the valves and efficient peripheral muscle pumping overcome the forces of gravity and prevent retrograde flow (reflux) of blood. 2, 3 However, venous stasis and hypertension result when the valves do not function properly, such as in valvular reflux, obstruction, or both. 4 Chronic venous insufficiency (CVI) of lower extremities is a common medical problem. It is caused by venous valve incompetence resulting in venous reflux and distal venous hypertension. Valve incompetence can be either primary or secondary. The primary (idiopathic) valve incompe-tence is thought to be caused by congenital defects, weakness and an abnormally distensible venous wall. [5] [6] [7] As the veins and valve rings expand, separation of the valve leaflets causes poor apposition and venous reflux, despite the relative absence of actual leaflet damage. Primary valve incompetence often involves valves in all three venous leg systems: superficial, deep and perforator veins. 6, 8 Secondary (post-phlebitic) valve incompetence develops after deep venous thrombosis and involves valves of the deep venous system. As venous thrombi organize there is damage or complete destruction of the venous valves leaving them incompetent and leading to chronic deep venous insufficiency (CDVI).
Clinical symptoms of CVI depend on the degree of valve incompetence and the extent of venous involvement. Symptoms can range from the minor cosmetic telangiectasia to disabling ulcerating skin conditions that may dominate an individual's way of life. If CDVI is left untreated, it results in pain, significant edema, sclerosis, and ulceration of the skin. 6, 9 For a long time, CVI has been treated conservatively with use of various compression techniques and devices. Varicose veins with predominant superficial valve insufficiency (SCVI) often have been managed surgically by ligation of the saphenofemoral junction and stripping of the saphenous vein. Recently developed catheter-based percutaneous techniques, including foam sclerotherapy and radiofrequency or laser ablation of the greater saphenous vein, are very popular alternatives to surgery and are preferentially used for effective treatment of varicose veins. [10] [11] [12] [13] The management of CDVI, however, still remains a problem. Selected patients can benefit from surgical valve repair, femoral vein transposition, or venous segment transplantation, 14, 15 but the majority of patients with CDVI, particularly patients with secondary valve insufficiency, are not candidates for these procedures due to obstructions or residual thrombus throughout the vein. Other approaches involve inverting a saphenous vein segment 16, 17 or constructing a neovalve by dissecting the intimal wall of the post-phlebitic vein to form cusps. This approach has an 85% ulcer-healing rate. 18 This review describes the initial designs and experimental evolution of a mechanical and bioprosthetic venous valve that can be implanted directly or percutaneously by using a transcatheter technique.
Surgically implanted bioprosthetic venous valvesexperimental work
Several attempts have been made to construct an experimental bioprosthetic venous valve. [19] [20] [21] [22] [23] In 1965, valved vein allografts were implanted into the femoral veins of 14 dogs, with 7% patency in the 1-month study. 19 In another study, both a gluteraldehyde-fixed human umbilical vein and liquid Pellethane bicuspid valve were fitted over a metallic mandrel. 20 Valves were surgically implanted into the jugular veins of 10 dogs. Each animal was implanted with a Pellethane valve in one external jugular vein (JV) and one umbilical vein valve in the other external JV. All implants clotted in 8 days. 21 Another platinum or pyrite carbon-covered titanium bileaflet valve was implanted into canine femoral veins. 22 Valves were patent and competent at 3 months, 22 but by 2 years extensive neointimal overgrowth resulted in valve failure. 22 Decellularized allograft venous valves were also not successful in treating venous insufficiency. Decellularized allograft venous valves were implanted into the jugular veins of six sheep, unaided by supportive anticoagulation. In all cases, these allografts failed due to thrombosis by week 6. 23 In this same study, the decellularized allografts were repopulated with donor smooth muscle and endothelial cells (ECs) and then implanted into the jugular veins of 12 sheep with eight autografts as controls in separate sheep. The cell-seeded allografts had improved results. At 12 weeks, nine of the 12 repopulated allografts were patent and competent without anticoagulation. Only two valves were rigid due to neointimal growth and one was thrombosed. These allografts performed almost as well as the eight autografts in the control group, which were all patent and competent at week 12. These findings indicate that early cellularization of bioprosthetic valves may prevent thrombosis and the fibrosis of the implanted valves. 23 
Percutaneous bioprosthetic venous valvesexperimental work
In 1981, Dotter proposed the implantation of a percutaneous artificial venous valve for CDVI patients for whom surgical treatment had failed, 24 but it was not until the 1990s that several percutaneous transcatheter-based valves were developed. [25] [26] [27] [28] [30] [31] [32] [33] These valves consisted of single, double, or triple cusp leaflets made of synthetic or biological materials attached to a carrier or frame, usually a selfexpanding metallic stent. These artificial venous valves were tested in animals and clinically in a few patients [34] [35] [36] with good short-term and disappointing long-term results.
Z-stent-based venous valves
In 1993, Uflacker reported on an artificial monocusp venous valve, which consisted of a thin polyether urethane membrane inside a single body Z-stent 25 (Figure 1 ). The valves were inserted percutaneously through a 10-Fr sheath into swine inferior vena cava (IVC). They worked well at 1-week follow-up on supine and upright cavograms. However, partial thrombosis appearing inside the valve cusp was of concern.
Thorpe, et al. in 2000 experimentally investigated a bicuspid venous valve made of the porcine small intestinal submucosa (SIS) mounted in a double body Z-stent. This model required a 16-Fr catheter for introduction. The valve showed promising in vitro and short-term results in the porcine model. 26 Bovine jugular vein valve mounted inside an expandable stent Gomez-Jorge, et al. reported the outcome of their 2-week study of the valve-stent device in a swine model. 27 Their bioprosthetic valve consisted of a trimmed segment of a gluteraldehyde-fixed, bovine external jugular-vein valve sutured inside a selfexpanding nitinol stent (Boston Scientific, Boston, MA, USA) ( Figure 2 ). These devices were introduced through 18-Fr sheaths and were deployed percutaneously into the IVC or iliac vein of 11 pigs. In the three short-term animals, the valves were patent and competent at 2 weeks. 27 De Borst, et al. 28 reported implantation of a similar gluteraldehyde-preserved bovine vein with a native vein valve in pig's iliac vein ( Figure 3 ). These gluteraldehyde-preserved xenografts sutured inside a memory-coded nitinol frame (n = 18) (VenPro Inc, Irvine, CA, USA) were deployed and explored in 18 iliac veins in 10 young pigs. In group I (vitamin K antagonist), seven stent valves were patent (three competent) at 2 weeks. One valve migrated and thrombosed. Thrombosis occurred in five out of 10 stent valves in group II (aspirin and clopidogrel) at 4 weeks follow-up. 28 Square stent-based bioprosthetic venous valve Pavcnik, et al. reported developments in the technology of prosthetic venous valves. [30] [31] [32] [33] [34] They have developed three types of bioprosthetic venous valves (BVV 1-3) (Figure 4 A-D) and evaluated their performance in animals. They consisted of a small leaflet of SIS 29 (Cook Biotech, West Lafayette, IN, USA) attached to different types of square stent frames. 30, 32, 33 These prototypes employed square stents as the foundation supporting a prosthetic valve biomaterial. SIS is a relatively acellular, nonimmunogenic, biodegradable, xenogenic, collagenbased biomaterial derived from the submucosal layer of porcine small intestine. SIS is a collagenbased extra-cellular matrix (ECM) material that provides a temporary scaffold for cellular colonization. 29 For their experimental animal work they used an ovine JV due to anatomical and functional similarities of the sheep JV with the human femoral vein. 23, [31] [32] [33] 37 The BVVs were designed to demonstrate several potential advantages for treatment of CDVI. The primary advantage of the BVV is the design of the cusp, which consists of a free edge of SIS and the native vein wall lined with ECs. In a long-term study, they implanted BVV1 in the jugular veins of 12 sheep and found that 24 valves out of 25 (four valves at 1 month, 10 valves at 3 months, and 10 valves at 6 months) were patent and only one BVV1 occluded at 1 month due to tilting of the valve. 31 The 22 valves were competent, but demonstrated limited cusp flexibility due to leaflet thickening. These findings indicate that BVV1 prevented occlusion of the valves but did not prevent the intimal hyperplasia of implanted SIS leaflets. 31 On 3 and 6-month specimens, the completely remodeled SIS matrix was covered with neointima consisting of ECs, fibroblasts with collagen deposits that caused leaflet thickening, which was most prominent at the leaflet base ( Figure 5 A and B) . The leaflet bases were incorporated into the vein wall with some foreign body giant cell reaction around the sutures and wires attached to the vein. 31 Immunohistochemical staining for both smooth muscle cell α-actin (Calbiochem, 1:200) and calponin (Biocare Medical, 1:100) indicated the presence of both myofibroblasts and fully differentiated smooth muscle cells within the SIS leaflets of the implanted valve ( Figure 5C ).
They explored several stent frame modifications to improve valve positioning during placement and to ensure its centering in the vein without tilting. The BVV2 gave the best results. The BVV2 stent frame was made of nitinol tubing. 32 It was similar to the BVV1 frame, except a second square stent without barbs was added to the midpoint of the original valve ( Figure 4C ). The BVV2 was placed through a 10-Fr sheath. Altogether, 28 BVV2 were implanted in the JVs of 14 sheep. All implanted valves remained in place completely centered and functioning well on immediate follow-up venograms. At 6 weeks follow-up, 26 valves remained functional. Only two oversized valves were incompetent and exhibited reflux.
The third generation valve, BVV3, was designed to prevent potential contact of free leaflet portions with the venous wall and assure continued leaflet coaptation, even with their possible shortening. The BVV3 frame was made of laser cut nitinol tubing and again had four barbs for valve stabilization ( Figure 4D) .
The round geometry of BVV3 allowed the leaflets to coapt and improved blood flow in the larger pockets of the valve, which prevented potential thrombus formation. Two gold markers on the nitinol frame facilitated precise anatomical orientation during valve deployment. The desired spacial orientation was achieved after deployment in all valves and all remained stable and completely functional on venography after implantation and at 5-week follow-up studies (Figure 6 A and B) . On gross examination, the remodeled SIS leaflets were free from the vein wall except at their distal parts where the SIS was thickened and attached to the vein (Figure 6 C and D) . 33 
Percutaneous autologous venous valve transplantationan experimental work
The limitation of the current techniques in the treatment of CDVI prompted exploration of the feasibility of endovascular transplantation of a stentsupported autologous natural valve as a possible treatment alternative. [38] [39] [40] [41] Dalsing, et al. explored in canines the endovascular transplantation of a JV valve supported with a 6 mm or 8 mm diameter Z-stent. 38 They deployed the valve stent assembly through a long 16-Fr sheath into the common or external iliac vein. At 1-4 weeks follow-up only one of five valves in an over-dilated recipient vein with a relatively high flow remained patent, the other four valves were occluded. 38 Ofenloch, et al. achieved better results in goats with the use of an endoscopically harvested JV segment containing a valve supported by a short 10 mm diameter Wallstent. 39 After venotomy, a 12-Fr sheath was used for placement of the valve stent device into the opposite JV. At 1 week, all five tested valves were competent. At 6 weeks, the transplanted vein segment was fully incorporated into the host vein. Angioscopically, five of six valves were competent and of normal appearance, only one valve was obliterated by recanalized thrombus. 39 Kucher, et al. achieved similar good results in canines comparing a standard femoral vein interposition with transplantation of a short 8 mm diameter nitinol Symphony stent-supported JV segment containing a valve into the femoral vein. 40 An 11-Fr sheath was used for placing the stent device covered from inside and outside by vein wall into the contra lateral femoral vein. Only one of seven dogs had bilateral femoral vein occlusions at 2 weeks followup. The remaining six had patent and wellfunctioning valves at 120 days in both the surgical grafts and the transplanted stent-supported JV segments. The surgical grafts exhibited minimal to moderate stenoses at the suture lines, not seen with the stented veins. 40 Pavcnik, et al. reported percutaneous autogenous venous valve (PAVV) transplantation in nine sheep. PAVV consisted of a vein segment containing a native valve that was attached to a stent template designed and handmade in a research laboratory. 41 The stent template consisted of two stainless steel square stents 13 mm or 15 mm in diameter to fit the ovine JV. 30 A valve containing a segment of the JV was surgically harvested and fixed with sutures and barbs to the inside of the stent template ( Figure 7A ). The valve device was then manually compressed and front loaded inside a 4 cm long chamber of the 13-Fr delivery sheath. This was followed by over-the-wire delivery into the contra lateral JV by a femoral vein approach. Transplanted PAVVs were studied by immediate and 3-month venograms, when the JVs were harvested for angioscopic evaluations in vitro. PAVV transplantation was successful in all nine animals. Good valve function with no reflux was observed on immediate or 3-month venograms in eight valves. Venoscopic examination at 3 months revealed intact, flexible, non-thickened valve leaflets in eight specimens (Figure 7 B and C) .
One PAVV exhibited normal function of one leaflet only; the other cusp was absent, accidentally cut during the transplantation procedure. All transplanted autologous valves were free of thrombus and incorporated into the vein wall of the host vessel. 41 
Percutaneous bioprosthetic venous valvesclinical pilot work
Patients with post-thrombotic damage of the deep vein valves, the most common cause of CDVI, are not good candidates for surgery due to obstructions or residual thrombus throughout the vein. [14] [15] [16] [17] An artificial venous valve is needed to treat CDVI after other options have failed. This treatment involves the insertion of a bioprosthetic venous valve that prevents venous reflux.
Percutaneous gluteraldehyde-preserved venous valve bioprosthesis
Serino 35 and Gale, et al. 36 reported treatment with a percutaneous artificial valve as part of a Phase I clinical trial. This gluteraldehyde-fixed bovine vein valve sutured to a nitinol self-expanding stent (Ven-Pro) was the artificial valve used in the clinical trials. It was implanted into deep femoral veins in five patients with venous stasis ulcers using an 18-Fr catheter. Implantations were performed first in the US and later in Europe. 35, 36 This valve design, however, was not suitable for venous implantation, and according to investigators' reports, four of five implants thrombosed despite adequate anticoagulation. One valve embolized into pulmonary artery. A new valve design is being tested. 35, 36 Square stent-based bioprosthetic venous valve Based upon promising experimental studies, 31-33 a 1-year clinical study was conducted in four institutions with approval of their Institutional Review Boards to determine the safety of the BVV3 implantation. Fifteen patients with advanced symptomatic CDVI in whom surgical treatment had failed, including eight patients with large venous ulcers, received the valve. A single BVV3 was deployed into the femoral vein percutaneously via a transjugular approach with a 12-Fr over-the-wire delivery catheter system (Figure 8 ). Pre-and postdeployment examinations included clinical examination, intravascular ultrasound, duplex ultrasound, descending venography and air platismography at 3 and 12 months. 42 Patients began warfarin (Coumadin) therapy 4 days prior to the BVV implantation at 5 mg/day to achieve a therapeutic international normalized ratio (INR) of 2.0-3.0 and were kept on this dose for 12 months. Prior to BVV implantation, patients received 5000 units of heparin. Successful placement of all 15 BVV3s was achieved without tilting or migration, although three valves were oversized. Immediate valve competence was seen in 14 limbs (93%). Follow-up studies at 3 and 12 months showed no migration of the implanted valves. Eleven valves (73.4%) were patent and four occluded (26.7%). Three valves occluded early (< 2 weeks), and one occluded late at 7 months. One valve occluded after placement into a duplicate femoral vein and three valves occluded in patients with a low level of INR or after discontinuation of Coumadin for spine surgery. At 3 months, only two valves remained fully functional.
At 12 months none of the valves remained competent. Thickening and rigidity of the leaflets of the non-thrombosed valves resulted in various degrees of reflux and caused their incompetence ( Figure 5 A-D). Clinically, however, valve implantation gave better results. Twelve of 15 patients (80%) had immediate and a 3-month clinical improvement that continued in nine patients (60%) at the 12month follow-up. Large venous ulcers healed completely in three of eight patients, improved in four, and only one giant ulcer did not show improvement. None of the 15 patients' clinical symptoms worsened after valve implantation. 42 
Discussion
A very long path with many small steps and tedious experimental research work is usually necessary to take a new idea to a successful clinical reality. At the present time more steps are still necessary for the percutaneous artificial venous valve implantation to become clinically useful. Some investigators [19] [20] [21] [22] [25] [26] [27] [28] did not continue their research, nor did any other investigator pursue their techniques. The BVV3 stent frame is, in our opinion, well suited to form a base for a bioprosthetic venous valve. It is easy to deliver, it self-centers, and remains stable in the vein. It allows good leaflet coaptation, even when the leaflets remodel and shorten, and prevents their contact with the venous wall. The SIS biomaterial for leaflets showed very promising early results with pliable leaflets and good valve function. In the long-term, however, because of the scaffolding nature of SIS with fibrotic transformation and excessive neointimal formation, the SIS leaflets thickened, became rigid and caused the valves to become incompetent. In our unpublished studies, leaflets treated or coated with cytostatic chemotherapy agents and non-steroidal anti-inflammatory drugs did not give better results than leaflets with untreated SIS. Potentially, there are a couple of routes to solve this problem. The first option is to bioengineer a method to cover leaf- lets' biomaterial with ECs to prevent neointimal hyperplasia and enhance valve functionality. Previous studies showed that leaflets lined with ECs prevented both neointima and intimal hyperplasia and enhanced the functionality of the valves. In a sheep model of allograft valve replacement, endothelialized valves performed significantly better than unseeded, decellularized valves that failed due to thrombosis, suggesting that ECs play a role in preventing thrombosis. 23 The other option is to use a more compatible biomaterial than SIS.
In conclusion, the percutaneous autogenous venous valve transplantation needs long-term studies to document the continued patency and function of the implanted valves. A close relationship with an interested device manufacturer and endovascular surgeons would accelerate the introduction of PAVV into clinical practice.
A manufactured, percutaneously implantable, non-immunogenic and non-thrombogenic bioprosthetic venous valve that remains patent and competent over time is an attractive alternative to direct venous valvular reconstruction or transplantation. Published results and the potential for effective treatment with bioprosthetic venous valves warrant additional research and may lead to an effective, minimally invasive treatment for deep chronic venous insufficiency.
